Reimbursed Care Access in Palestine, State of

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. This aligns with Palestine’s obligations as a party to the international psychotropics control framework. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Palestine is a party to the 1971 UN Convention on Psychotropic Substances, which requires prohibition of non‑medical uses of MDMA absent specific licensing. #

There is no public record of national approval, routine clinical programs, or reimbursed availability of esketamine (Spravato) within Palestinian health services; Palestinian hospitals and health authorities primarily deploy essential anesthetic drugs and do not appear to have established supervised esketamine psychiatric programs or REMS‑style clinics. Ketamine itself is an essential injectable anesthetic on the WHO Model List of Essential Medicines and is used in Palestinian clinical settings (including emergency and surgical care), but esketamine as a licensed psychiatric nasal spray is not documented as an approved or reimbursed product in Palestine. # #

Ketamine is recognized globally and within clinical practice in the region as an essential injectable anesthetic and is used in Palestinian hospitals for anesthesia and emergency/trauma care; it appears in supply chains for operative and acute settings but formal reimbursed psychiatric ketamine programs (for depression or PTSD) are not documented as established, broadly reimbursed services in Palestinian public health systems. Specifically:

- International guidance and model lists identify ketamine as an essential medicine for anesthesia, supporting its authorized medical use in health systems, including in Palestine’s hospitals and emergency services. #

- Reporting from Gaza and regional coverage since 2023–2025 indicate ketamine is an actively used battlefield/trauma anesthetic in Palestinian hospitals but also repeatedly subject to shortages and constrained supply in conflict contexts; these reports document clinical dependence on ketamine for anesthesia and analgesia in emergency settings rather than for standardized, reimbursed psychiatric programs. (examples of reporting on ketamine use and shortages in Gaza hospitals are available). # #

- Practical implication: licensed ketamine (injectable) is available for medical/anaesthetic indications in Palestinian healthcare contexts and used in urgent care, but ketamine for psychiatric indications is effectively off‑label, not part of a nationally reimbursed psychiatric standard of care, and constrained by supply and operational limitations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Palestine’s obligations under international psychotropic drug treaties mean research‑only pathways would be required for any medical access. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No public evidence of regulated medical programs or reimbursement for 5‑MeO‑DMT in Palestine. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no documented legalized medical or reimbursed framework for ibogaine in Palestinian health services. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT are controlled under the psychotropics framework; therefore ayahuasca has no authorized therapeutic/reimbursed pathway in Palestine outside permitted research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of clinical programs, approvals, or reimbursement for mescaline in Palestinian health systems. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The substituted phenethylamines (2C family) are controlled under international and national law and lack sanctioned medical/reimbursed pathways in Palestine. #